ArticleScience advances2023
Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review.Medical oncology (Northwood, London, England) · 2026Pooled it
- Deciphering the biological underpinnings behind prognostic MRI-based imaging signatures in breast cancer: a systematic review.Journal of translational medicine · 2025Pooled it
- Association of radiomic features with genomic signatures in thyroid cancer: a systematic review.Journal of translational medicine · 2024Pooled it
- Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.Cancer research communications · 2025Trial
- Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).Hepatology (Baltimore, Md.) · 2026Article
- Integrating Multimodal MRI Habitat and Transformer-Based Pathomics to Predict High-Risk Molecular Subtypes and Explore Biological Mechanisms in Adult Diffuse Gliomas.CNS neuroscience & therapeutics · 2026Article
- Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging.European radiology · 2026Article
- Spatial habitat radiomics predicts tertiary lymphoid structure status and identifies an IDO1Journal for immunotherapy of cancer · 2026Article
- Deciphering the rules of regulated cell death subroutines by in silico methods.Journal of advanced research · 2026Review
- Noninvasive Characterization of Tumor Heterogeneity in HNSCC: From Clinical Utility to Biological Correlates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Noninvasive Multi-Omics Radiomic Model Integrating scRNA-seq and Bulk RNA-seq for Hepatocellular Carcinoma Prognosis.Journal of imaging informatics in medicine · 2026Article
- Chinese expert concern and consensus on applications of artificial intelligence in clinical cancer imaging.Insights into imaging · 2026Article
- CT-based Intratumoral Heterogeneity Score for Preoperative Prediction of Lymphovascular Invasion and Prognosis in Lung Adenocarcinoma: A Multicenter Validation and Radiogenomic Interpretation.Annals of surgical oncology · 2026Article
- Multidimensional deep learning for grading and prognostic assessment of intrahepatic mass-forming cholangiocarcinoma.Insights into imaging · 2026Article
- Article
- Deep learning-driven MRI radiomics reveals biological subtypes and predicts recurrence risk in rectal cancer.NPJ precision oncology · 2026Article
- Plasma proteome-metabolome signatures enable non-invasive early detection and lymph node risk stratification in breast cancer.Molecular cancer · 2026Article
- Decoding Occult Cervical Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma: From AI-Driven Multimodal Fusion to Clinical Translation.Current oncology reports · 2026Review
- Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response.Nature biomedical engineering · 2026Article
- PET/CT-based quantification of intratumoral heterogeneity for predicting pathological complete response in breast cancer patients treated with neoadjuvant chemotherapy: A multicentre study.European journal of nuclear medicine and molecular imaging · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intratumor heterogeneity (ITH) profoundly affects therapeutic responses and clinical outcomes. However, the widespread methods for assessing ITH based on genomic sequencing or pathological slides, which rely on limited tissue samples, may lead to inaccuracies due to potential sampling biases. Using a newly established multicenter breast cancer radio-multiomic dataset (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.